Adenocarcinoma of the Prostate, Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage I Prostate Cancer, Stage IV Prostate Cancer
Conditions
Brief summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel and prednisone together with sunitinib malate may kill more tumor cells. PURPOSE: This pilot phase I/II trial studies the side effects and best way to give docetaxel and prednisone together with sunitinib malate and to see how well it works in treating patients with prostate cancer that progressed after hormone therapy.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the response by prostate specific antigen (PSA) of docetaxel/prednisone plus sunitinib (sunitinib malate) in chemotherapy-naive, hormone refractory prostate cancer subjects with biochemical relapse. SECONDARY OBJECTIVES: I. To determine the objective response rate (ORR) and duration of response (DR) in subjects with measurable disease. II. To determine overall survival (OS) and time to progression (TTP). III. To evaluate the safety and tolerability of sunitinib in combination with docetaxel and prednisone. OUTLINE: Patients receive docetaxel intravenously (IV) over 60 minutes on day 1, prednisone orally (PO) twice daily (BID) on days 1-21, and sunitinib malate PO once daily (QD) on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for 3 years.
Interventions
DRUGsunitinib malate
Given PO
DRUGdocetaxel
Given IV
DRUGprednisone
Given PO
Sponsors
Sanofi
John P. Fruehauf
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have a histological diagnosis of adenocarcinoma of the prostate * Age ≥ 18 * Subjects must have metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy by one or more of the following (despite androgen deprivation and anti-androgen withdrawal when applicable) check all that apply. * Subjects may have received prior surgery. However, at least 21 days must have elapsed since completion of surgery and Subject must have recovered from all side effects. * Subjects must have adequate hepatic function as defined by: * a serum bilirubin ≤1.5 x the institutional upper limit of normal (IULN), * Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) ≤2.5 x the institutional upper limit of normal obtained within 14 days prior to start of therapy * Subjects must have 2 pre-study PSA \> 2ng/ml at least 1 week apart within 28 days prior to start of therapy * Subjects must have been surgically or medically castrated. If method of castration is luteinizing hormone-releasing hormone (LHRH) agonist (leuprolide or goserelin), then the Subject should be willing to continue the use of LHRH agonists. Castration using LHRH agonist should not be interrupted and subjects who have stopped treatment should be willing to restart. * Subjects must not take vitamins, herbs, or micronutrient supplement within 28 days prior to start of therapy. * Prior external beam radiation therapy (to less than 30% of the bone marrow only) is allowed. This includes prior use of samarium, but subjects can not have received prior strontium. At least 28 days must have elapsed since the completion of radiation therapy and the Subject must have recovered from side effects. Soft tissue disease which has been radiated in the prior 2 months is not assessable as measurable disease. * Subjects with a history of myocardial infarction are not eligible. Subjects must have a baseline EKG to rule out underlying cardiac disease within 42 days prior to registration. Subjects with a history of cardiac disease, specifically congestive heart failure (CHF) are ineligible unless their disease is well-controlled. Subjects with history of cardiovascular accident (CVA) or atrial fibrillation are ineligible. * Subjects with a history of brain metastases or who currently have treated or untreated brain metastases are not eligible. Subjects with clinical evidence of brain metastases must have a brain CT or MRI negative for metastatic disease within 56 days prior to registration. \*Liver function tests should be evaluated prior to each treatment. * Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Subjects must have an adequate renal function as defined by: * a serum creatinine ≤1.5 x the institutional upper limit of normal obtained within 14 days prior to start of therapy and a urine protein: creatinine (UPC) ratio of ≤ 1.0. * Subjects must have the following hematological criteria (minimal values): * Absolute neutrophil count ≥ 1,500/mm³ * Hemoglobin of ≥ 8.0gm/dL, * White blood cell count ≥ 2500, * Platelets ≥ 75,000/mm³ * Subjects must be able to take oral medications
Exclusion criteria
* Subjects must not have received chemotherapy, biologic therapy or any other investigational drug for any reason within 28 days prior to start of therapy and must have recovered from toxicities of prior therapy to grade 1 or less with the exception of alopecia. * Subjects may not have ongoing problems with bowel obstruction or short bowel syndrome characterized by grade 2 or greater diarrhea or malabsorptive disorders. * Men of child bearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. * Subjects with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 will be excluded * Subjects should not have psychological, familial, sociological, or geographical conditions that do not permit medical follow-up or compliance with the study protocol. * Subjects should not have any medical life-threatening complications of their malignancies * Subjects should not have a known severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, active uncontrolled infection, or HIV). * Subjects should not have current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study. * Baseline blood pressure of \< or equal to 150/100 mmHg. Subjects with a blood pressure reading above this level should be initiated on anti-hypertensive therapy and may be considered for protocol treatment when their blood pressure is adequately controlled. * Subjects with New York Heart Association (NYHA) Grade II or greater congestive heart failure are not eligible. Subjects must have a baseline multiple gated acquisition scan (MUGA) or Echocardiogram with a calculated ejection fraction \> or equal to 50%. * Subjects with clinically significant peripheral vascular disease are not eligible. * Subjects with evidence of bleeding diathesis or coagulopathy are not eligible. * Subjects with central nervous system or brain metastases are not eligible. * Subjects who had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study are not eligible. * Subjects with minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0 are not eligible. * Subjects with history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess are not eligible. * Subjects with serious, non-healing wound, ulcer, or bone fracture are not eligible. * Subjects who are diagnosed of any other malignancy except non-melanomatous skin cancer in the past 5 years are not eligible. * Subjects receiving anticoagulation therapy (e.g. Coumadin) prior to registration are not eligible. Subjects are permitted to have prior Coumadin for prophylaxis against agents that might produce blood clots. Subjects with low dose Aspirin (86mg) are acceptable. * Subjects with active thrombophlebitis or hypercoagulability are not eligible. Subjects with known history of pulmonary embolus are not eligible. * All Subjects must be informed and must sign and give written informed consent in accordance with institutional and federal guidelines. Subjects who are unable to comply with study and/or follow-up procedures are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prostate Specific Antigen (PSA) Response Rate | Baseline, every 3 weeks, at study termination, and then for 3 years | Defined by \>= 30% decline in PSA from baseline for at least 3 months during study entry. Response rates will be expressed with two-sided exact binomial confidence intervals. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. Associations between PSA response and tumor response will also be examined by Fisher's exact test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rates of Tumor Response (ORR) | Every 2 months | Response rates will be expressed with two-sided exact binomial confidence intervals. The difference of response rates between different pre-treatment pathological stages or Gleason scores will also be examined by Fisher's exact test. Associations between PSA response and tumor response will also be examined by Fisher's exact test. |
| Duration of Response (DR) | Up to 3 years | Response rates will be expressed with two-sided exact binomial confidence intervals. |
| Time to Progression (TTP) by PSA Response and Disease Response | Baseline, every 3 weeks, at study termination, and then for 3 years | Defined as an absolute increase in PSA of at least 2 ng/ml. For subjects with measurable disease, Response Evaluation Criteria In Solid Tumors (RECIST) criteria will be used. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. Associations between PSA response and tumor response will also be examined by Fisher's exact test. |
| Survival | At 2 and 3 years | Quantitative Kaplan-Meyer estimates of progression-free survival and overall survival will be determined. |
| Qualitative and Quantitative Toxicity | Every 3 weeks and at study termination | Severity will be categorized by toxicity grade according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Categorical analysis of toxicities will be performed. |
Countries
United States
Participant flow
Recruitment details
Study start date: July 2009 Primary completion date: October 2011 Study completion date: November 2011
Participants by arm
| Arm | Count |
|---|---|
| Chemotherapy and Enzyme Inhibitor Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
prednisone : Given PO
docetaxel : Given IV
sunitinib malate : Given PO | 4 |
| Total | 4 |
Baseline characteristics
| Characteristic | Chemotherapy and Enzyme Inhibitor |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Gender Female | 0 Participants |
| Gender Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 1 / 4 |
| serious Total, serious adverse events | 0 / 4 |
Outcome results
Primary
Prostate Specific Antigen (PSA) Response Rate
Defined by \>= 30% decline in PSA from baseline for at least 3 months during study entry. Response rates will be expressed with two-sided exact binomial confidence intervals. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. Associations between PSA response and tumor response will also be examined by Fisher's exact test.
Time frame: Baseline, every 3 weeks, at study termination, and then for 3 years
Secondary
Duration of Response (DR)
Response rates will be expressed with two-sided exact binomial confidence intervals.
Time frame: Up to 3 years
Secondary
Qualitative and Quantitative Toxicity
Severity will be categorized by toxicity grade according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Categorical analysis of toxicities will be performed.
Time frame: Every 3 weeks and at study termination
Secondary
Rates of Tumor Response (ORR)
Response rates will be expressed with two-sided exact binomial confidence intervals. The difference of response rates between different pre-treatment pathological stages or Gleason scores will also be examined by Fisher's exact test. Associations between PSA response and tumor response will also be examined by Fisher's exact test.
Time frame: Every 2 months
Secondary
Survival
Quantitative Kaplan-Meyer estimates of progression-free survival and overall survival will be determined.
Time frame: At 2 and 3 years
Secondary
Time to Progression (TTP) by PSA Response and Disease Response
Defined as an absolute increase in PSA of at least 2 ng/ml. For subjects with measurable disease, Response Evaluation Criteria In Solid Tumors (RECIST) criteria will be used. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. Associations between PSA response and tumor response will also be examined by Fisher's exact test.
Time frame: Baseline, every 3 weeks, at study termination, and then for 3 years